Mark A Wingertzahn
Overview
Explore the profile of Mark A Wingertzahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Couroux P, Kunjibettu S, Hall N, Wingertzahn M
Ann Allergy Asthma Immunol
. 2009 Feb;
102(1):62-8.
PMID: 19205288
Background: Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR). Objective: To evaluate the time to onset of action of ciclesonide, 200 microg/d, in patients with...
12.
Patel P, Patel D, Kunjibettu S, Hall N, Wingertzahn M
Ear Nose Throat J
. 2008 Jun;
87(6):340-53.
PMID: 18561117
Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis. We conducted a randomized, double-blind, parallel-group, placebo-controlled study to evaluate the time to onset of action of ciclesonide...
13.
Wingertzahn M, Derebery M, Nelson H
Allergy Asthma Proc
. 2007 May;
28 Suppl 1:S18-24.
PMID: 18307840
Intranasal corticosteroids (INCSs) provide safe and effective treatment of allergic rhinitis (AR). Currently available INCSs differ in terms of the components included in each formulation that may influence efficacy, tolerability,...
14.
Meltzer E, Kunjibettu S, Hall N, Wingertzahn M, Murcia C, Berger W, et al.
Ann Allergy Asthma Immunol
. 2007 Feb;
98(2):175-81.
PMID: 17304887
Background: Ciclesonide is an intranasal corticosteroid approved for the treatment of allergic rhinitis (AR). Objective: To evaluate the efficacy, safety, and quality-of-life benefits of intranasal ciclesonide, 200 microg once daily,...
15.
Ratner P, Wingertzahn M, van Bavel J, Hampel F, Darken P, Hellbardt S, et al.
Ann Allergy Asthma Immunol
. 2006 Dec;
97(5):657-63.
PMID: 17165276
Background: Ciclesonide is an investigational corticosteroid under development for treatment of allergic rhinitis. Ciclesonide is converted to active metabolite, desisobutyryl-ciclesonide (des-CIC), by upper and lower airway esterases. In vitro studies...
16.
Ratner P, Wingertzahn M, van Bavel J, Hampel F, Darken P, Shah T
J Allergy Clin Immunol
. 2006 Nov;
118(5):1142-8.
PMID: 17088141
Background: Allergic rhinitis (AR), an inflammatory disease of the nasal mucosa, affects approximately 25% of adults and 40% of children in the United States. Ciclesonide nasal spray is a corticosteroid...
17.
Nave R, Wingertzahn M, Brookman S, Kaida S, Matsunaga T
J Clin Pharmacol
. 2006 Mar;
46(4):461-7.
PMID: 16554455
Ciclesonide is an intranasal corticosteroid in development for the treatment of allergic rhinitis. To assess the safety, tolerability, and pharmacokinetics of ciclesonide, adult healthy volunteers and asymptomatic subjects with seasonal...
18.
Rehman K, Wingertzahn M, Teichberg S, Harper R, Wapnir R
Dig Dis Sci
. 2003 May;
48(4):755-60.
PMID: 12741467
Previous experiments have shown that a soluble fiber, gum arabic (GA), enhances water, electrolyte, and glucose absorption in animal models of diarrhea. The mechanisms implicated in this effect have not...
19.
Wingertzahn M, Rehman K, Altaf W, Wapnir R
Pediatr Res
. 2003 Feb;
53(3):434-9.
PMID: 12595591
Zinc has been recognized as an antioxidant with potential for chronic and acute effects. Oxidative damage produced by free radicals, including nitric oxide (NO), is responsible for certain types of...